While both genes were expressed at a higher level in the blood of HNSCC patients compared to that of corresponding controls, a trend of decline in expression of both BRCA2 and XPD from stage II through stage IV was observed, mirroring the expression pattern observed in the tumour tissue, in both cases. The gene discussed is ERCC2; the disease is head and neck squamous cell carcinoma.